J&J Ollin Biosciences Deal: Why the Price Tag Keeps Shifting
The Ollin Biosciences deal nets J&J a Phase 3 eye-disease antibody - but the $2.2bn and $3.4bn headlines both miss the confirmed terms.
Markets
Delayed · 13:32 UK
Topic
Every Financial News story tagged JNJ, newest first.
The Ollin Biosciences deal nets J&J a Phase 3 eye-disease antibody - but the $2.2bn and $3.4bn headlines both miss the confirmed terms.